A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia

Summary

This clinical trial is a multicenter, single-arm, open-label study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of olutasidenib administered orally twice daily under fasting conditions for one cycle of 28 days in at least 3 Japanese patients with relapsed or refractory IDH1 mutation-positive AML.

Timeline

Start

2026-06

Primary completion

2030-09

Completion

2030-09

Drugs

Indications